Episode Details
Back to Episodes
Can Damaged Optic Nerve Cells Be Made Young Again? The First Human Glaucoma Reprogramming Trial Has Begun
Description
This audio article is from VisualFieldTest.com.
Read the full article here: https://visualfieldtest.com/en/can-damaged-optic-nerve-cells-be-made-young-again-the-first-human-glaucoma-reprogramming-trial-has-begun
Test your visual field online: https://visualfieldtest.com
Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support
Excerpt:
Can Damaged Optic Nerve Cells Be Made Young Again? The First Human Glaucoma Reprogramming Trial Has Begun As of August 28, 2026, the first human trial of partial epigenetic reprogramming is underway. Life Biosciences’ experimental therapy, ER-100, is being tested in adults with open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy. The first participant was dosed on June 9, 2026, after the United States Food and Drug Administration cleared the investigational new drug application in January. () The treatment is not a stem-cell transplant. It does not replace the optic nerve with new tissue. Instead, it attempts to make surviving retinal ganglion cells behave more like younger cells by temporarily activating three powerful gene-regulating proteins: OCT4, SOX2, and KLF4, collectively called OSK. The central question is extraordinary but precise: > Can an old or injured retinal ganglion cell recover enough of its youthful function to preserve, or perhaps partially restore, vision? The answer is not yet known. Animal studies provide a credible biological rationale, including improvements in retinal ganglion-cell activity, optic-nerve axon measurements, DNA methylation patterns, and visual behavior. But the human trial is small, primarily designed to test safety, and has not yet produced publicly reported efficacy results. --- The Short Answer Fact In mice, OSK expression has: Restored aspects of youthful DNA methylation and gene-expression patterns. Increased retinal ganglion-cell survival after optic-nerve injury. Promoted optic-nerve axon regeneration after an experimental crush injury. Improved pattern electroretinogram signals. Improved visually guided behavior in a mouse glaucoma model. Produced prolonged visual improvement after glaucoma-like damage. Shown no obvious retinal tumors or gross retinal structural abnormalities in long-term mouse studies. () In nonhuman primates, company-reported studies of a non-arteritic anterior ischemic optic neuropathy-like injury found improved retinal ganglion-cell electrical activity and increased axon-density measurements after treatment. These findings have been presented by Life Biosciences and described in a patent, but the most detailed nonhuman-primate data have not yet appeared as a fully independent peer-reviewed clinical efficacy publication. () Inference ER-100 is biologically more likely to help surviving but dysfunctional retinal ganglion cells than to replace cells that have already died. It may also help some damaged axons resume function or grow over limited distances. However, there is currently no direct evidence that ER-100 can rebuild a completely lost human optic nerve, restore all missing retinal ganglion cells, or correctly reconnect new axons with the visual centers of the brain. Prediction The most realistic early success would be: Evidence that the therapy reaches retinal ganglion cells. No unacceptable inflammation, pressure elevation, retinal damage, or uncontrolled cellular reprogramming. A reproducible improvement in retinal electrical activity or visual-field performance in a subset of patients. A dramatic restoration of advanced glaucoma vision is possible in theory but remains unlikely based on the present evidence. --- What Is ER-100? ER-100 is an intravitre